GlaxoSmithKline Price to Earning Trend from 2010 to 2020

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:4em;padding-top: 25px;;'>GP</div>
GSK -- USA Stock  

Fiscal Quarter End: 30th of June 2020  

GlaxoSmithKline PLC Revenues is increasing as compared to previous years. The last year's value of Revenues was reported at 33.75 Billion. The current Research and Development Expense is estimated to increase to about 4.7 B, while Cost of Revenue is estimated to decrease to under 11.4 B.

Search Historical Trends

 
Refresh
Check GlaxoSmithKline PLC financial statements over time to gain insight into the future company performance. Apply historical fundamental analysis to find patterns among financial statement drivers such as Direct Expenses of 10 B, Consolidated Income of 4.6 B or Cost of Revenue of 11.4 B, as well as many exotic indicators such as Interest Coverage of 158, Long Term Debt to Equity of 2.7 or Calculated Tax Rate of 23.02. This can be a perfect complement to check GlaxoSmithKline PLC Valuation or Volatility. It can also complement various GlaxoSmithKline PLC Technical models. Please check the analysis of GlaxoSmithKline PLC Correlation with competitors.

GlaxoSmithKline Price to Earning Marginal Breakdown

Showing smoothed Price to Earnings Ratio of GlaxoSmithKline PLC with missing and latest data points interpolated. An alternative to [PE] representing the ratio between [Price] and [EPSUSD].
View

47.28 

          10 Years Trend
 Price to Earnings Ratio 
      Timeline 

GlaxoSmithKline Price to Earning Regression Statistics

Arithmetic Mean 27.12
Geometric Mean 21.38
Coefficient Of Variation 81.99
Mean Deviation 16.48
Median 19.02
Standard Deviation 22.24
Sample Variance 494.53
Range 75.08
R-Value 0.44
Mean Square Error 441.32
R-Squared 0.20
Significance 0.17
Slope 2.97
Total Sum of Squares 4,945

GlaxoSmithKline Price to Earning Over Time

2010  11.96 
2011  14.19 
2012  14.63 
2013  14.33 
2014  23.94 
2015  7.85 
2016  82.93 
2017  41.81 
2018  20.43 
2019  19.02 
2020  47.28 

About GlaxoSmithKline PLC Financial Statement Charts

There are typically three primary documents that fall into the category of financial statements. These documents include GlaxoSmithKline PLC income statement, its balance sheet, and the statement of cash flows. GlaxoSmithKline PLC investors use historical funamental indicators, such as GlaxoSmithKline PLC's Price to Earning, to determine how well the company is positioned to perform in the future. Although GlaxoSmithKline PLC investors may use each financial statement separately, they are all related. The changes in GlaxoSmithKline PLC's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on GlaxoSmithKline PLC's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on GlaxoSmithKline PLC Financial Statements. Understanding these patterns can help to make the right decision on long term investment in GlaxoSmithKline PLC. Please read more on our technical analysis and fundamental analysis pages.
 2017 2018 2019 2020 (projected)
Receivables5.67 B6.08 B6.87 B5.97 B
Inventories5.56 B5.48 B5.95 B5.09 B
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. GlaxoSmithKline PLC operates under Drug Manufacturers - General classification in USA and is traded on BATS Exchange. It employs 99437 people.

Did you try this?

Run Portfolio Rebalancing Now

   

Portfolio Rebalancing

Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
All  Next Launch Module

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check the analysis of GlaxoSmithKline PLC Correlation with competitors. Please also try Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page